Synonyms: CEACIDE® | hMN14
Compound class:
Antibody
Comment: Labetuzumab is a humanised mouse monoclonal antibody targeting CEACAM5 (CD66e), a tumour marker that can be measured in serum.
Labetuzumab can be labelled with radioactive isotopes such as yttrium-90 and iodine-131, providing targeted radioimmumotherapy. Labetuzumab has been used to generate an antibody-drug conjugate (ADC) called labetuzumab govitecan, in which the antibody is covalently bound to SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan. |
Bioactivity Comments |
The preparation and use of labetuzumab appears to be covered by patent US6676924 [1] although in the absence of peptide sequences for the antibody this cannot be definitively confirmed. However, this patent does not provide a binding affinity value for the interaction between the antibody and its antigen, but the antibody'smechanism of action and primary target are substantiated by the results of biological assays. |
Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|